Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Oxabact Study in primary hyperoxaluria
ISRCTN63711065Phase 3Completed
- Sponsor
- OxThera AB
- Start
- Jan 2010
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Primary hyperoxaluria (PH) comparing Oxabact with Placebo (2 arms). Primary endpoint: Percentage change in urinary oxalate at week 24. Started Jan 2010; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on ISRCTN63711065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63711065.